A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine
the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly
diagnosed AML who are unfit for intensive chemotherapy (ICT). This study will comprise 2
phases: a Dose Escalation Phase and an Expansion Phase, in which all subjects will receive a
combination of CPX-351 and venetoclax.